Our Commitment to Safety Communication

Verified safety updates from ongoing ocrelizumab clinical trials and post-marketing experience

The Prescribing Information is the primary source of information on the known and potential risks of ocrelizumab for relapsing forms of multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS).

As of October 2019, more than 130,000 patients1 with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 140,000 patient-years and more than 500,000 infusions administered.2

>6,000 patients in clinical trials and the open-label extension. >125,000 patients in the post-marketing setting.

The following ocrelizumab global safety updates are available. Click below to learn more:

Updated Safety Analysis

Learn More

Additional Topics of Interest

Learn More

Post-marketing Commitments

Learn More

Indication:

Ocrelizumab is indicated for the treatment of: 

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults

 

Report an Adverse Event:
Phone: (888) 835-2555
Hours: 24 hrs/day, 7 days/week

Medical Communications:
Submit a question online
Phone: (800) 821-8590
Hours: Monday - Friday, 5am - 5pm PT

Contact an MSL:
Request follow-up with a Genentech medical science liaison (MSL)

References:

1.
Genentech data on file: September 30, 2019, post-marketing experience; July 31, 2019, clinical trials data cut-off

2.

Genentech data on file: September 30, 2019, post-marketing experience; January 7, 2019, clinical trials data cut-off